Low antiviral uptake of nirmatrelvir/ritonavir and molnupiravir in adult patients with COVID-19 in Taiwan in 2022
Nirmatrelvir/ritonavir and molnupiravir were poorly used in the treatment of adult COVID-19 patients in Taiwan during the pandemic in 2022, especially in moderate-to-high risk groups for progression to severe COVID-19.
Authors
- Whitney Burton
- Phung‐Anh Nguyen (ORCID: https://orcid.org/0000-0002-7436-9041)
- Júlia Spinardi (ORCID: https://orcid.org/0000-0002-4324-0317)
- Florence Lefebvre d’Hellencourt (ORCID: https://orcid.org/0009-0007-3794-4864)
- Phan Thanh Phuc
- Bulent Taysi (ORCID: https://orcid.org/0009-0003-2318-7293)
- Jason C. Hsu (ORCID: https://orcid.org/0000-0003-2997-2404)
- Fu‐Der Wang (ORCID: https://orcid.org/0000-0002-7963-7113)
- David Lee (ORCID: https://orcid.org/0009-0006-5423-4525)
- Nguyen Thi Hien (ORCID: https://orcid.org/0009-0006-2371-434X)
- Moe H. Kyaw (ORCID: https://orcid.org/0000-0002-7633-271X)
- Y. W. Chang
- Shiue-Ming Lin
- Yang Chieh
Institutions
- National Yang Ming Chiao Tung University (TW)
- Pfizer (United States) (US)
- Taipei Medical University Hospital (TW)
- Taipei Medical University (TW)
Publication Details
- Journal
- Journal of Global Health
- Published
- 2024-11-08
- DOI
- https://doi.org/10.7189/jogh.14.05032
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Pfizer
- Taipei Medical University
- National Science and Technology Council